Tel +49 (0)30 560 42240, Mon - Fri, 9am - 1pm

Research and studies

This latest study confirms the findings on the extension of the telomeres in a randomized, double-blind, placebo-controlled study in vivo (human) of TA-65® over a period of one year.
Overall, this study demonstrates that telomerase activators such as TAT2 can represent a new class of therapeutics that enhance immune function at a fundamental cellular level, complement existing drugs for the treatment of HIV / AIDS and a variety of age-related disorders with immune deficiency.